Choosing Between Oral and Injectable PsO Therapy

This episode, titled ‘Choosing Between Oral and Injectable PsO Therapy,’ features panelists discussing how route of administration influences systemic treatment decisions in plaque psoriasis. Historically, patients who prioritized efficacy were often steered toward biologic therapy even when they initially preferred an oral medication. The panel explains that this conversation is changing as newer oral therapies demonstrate greater efficacy and provide clinicians with more competitive alternatives.

Faculty discuss why patient preference cannot be reduced to simply choosing a pill over a needle. Injection frequency, ease of administration, safety, travel, refrigeration, and comfort with self-injection all influence how patients perceive biologic therapy. Some patients may be comfortable with an injection given only a few times per year, while others strongly prefer the familiarity and flexibility of a daily oral medication.

The experts also describe how newer oral options may be especially reassuring for patients taking their first step into systemic therapy. An oral medication may feel less intimidating and offers the perceived flexibility of stopping therapy without the prolonged exposure associated with some injectable agents. At the same time, widespread use of injectable therapies in other areas of medicine may be making some patients more comfortable with injections.

In the next episode, ‘Understanding the Pathophysiology of PsO,’ panelists will review the pathophysiology of psoriasis and explain how PDE4, TYK2, and IL-23–targeted oral therapies act within key inflammatory pathways.